MP24-14 PEMBROLIZUMAB (PEMBRO) PLUS OLAPARIB IN PATIENTS WITH DOCETAXEL-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): UPDATED RESULTS FROM KEYNOTE-365 COHORT A WITH A MINIMUM OF 11 MONTHS OF FOLLOW-UP FOR ALL PATIENTS

Luke T. Nordquist,Evan Y. Yu,Josep M. Piulats,Gwenaelle Gravis,Peter C.C. Fong,Tilman Todenhoefer,Brigitte Laguerre,Jose Angel Arranz-Arija,Stéphane Oudard,Christophe Massard,Michael Stoeckle,Joan Carles,Michael Kolinsky,Marinela Augustin,Howard Gurney,Ali Tafreshi,X. T. Li,Christian Heinrich Poehlein,Charles Schloss,Johann S. de Bono

MP24-14 PEMBROLIZUMAB (PEMBRO) PLUS OLAPARIB IN PATIENTS WITH DOCETAXEL-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): UPDATED RESULTS FROM KEYNOTE-365 COHORT A WITH A MINIMUM OF 11 MONTHS OF FOLLOW-UP FOR ALL PATIENTS

2021

INTRODUCTION AND OBJECTIVE:The phase 1/2 KEYNOTE-365 study (NCT02861573) previously showed that pembro+olaparib was associated with antitumor activity and acceptable safety in molecularly unselecte...

Keywords:

Olaparib
in patient
Pembrolizumab
Prostate cancer
castration resistant
Internal medicine
Oncology
Docetaxel
Medicine
antitumor activity
Cohort

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations